BIO:ON Insight #3 · Jun 15, 2026
One company bought it. Some proved it. Two rivals built it together.
GSK pays $10.6B for Nuvalent's lung cancer pipeline, Korean biotechs bring muscle- and heart-sparing obesity data to ADA, and Gilead and Merck's once-weekly HIV pill wins two Phase 3 trials. Buy, prove or partner?
What I learned this week
Writing this issue, what stuck with me is that innovation rarely finishes on its own. Before one good drug reaches patients, someone has to fund it, someone has to generate the data, and someone has to decide to combine their molecule with a rival's. Next time a big deal hits the news, before looking at the price, ask "which road did this company choose?" The same number will read very differently. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- Pipeline Analysis
GSK acquires Nuvalent for $10.6B
GSKNuvalent
- Clinical Trials
Gilead and Merck report positive Phase 3 for a once-weekly oral HIV regimen
GileadMerck & Co.
- Clinical Trials
ADA 2026: Korean biotechs present data
AI summary
- 1GSK is buying Nuvalent, with its next-generation lung cancer targeted therapies, for $10.6B.
- 2Korean biotechs showed obesity data beyond weight loss — muscle, heart and liver protection — at ADA 2026.
- 3Gilead and Merck's once-weekly oral HIV treatment succeeded in two Phase 3 trials at once.
Relevant rolesBDClinical developmentCMC & QA
Summary and tags generated by AI from the issue text.
References
- 1.GSK to acquire Nuvalent for $10.6B (opens in a new tab)
GSK press release
- 2.Korean biotechs' obesity and metabolic data at ADA 2026 (opens in a new tab)
The Fact · Etoday roundup
- 3.
Related insights
Other issues covering the same companies, drugs or topics